These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1019 related articles for article (PubMed ID: 34431693)

  • 21. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.
    Kaku Y; Kuwata T; Zahid HM; Hashiguchi T; Noda T; Kuramoto N; Biswas S; Matsumoto K; Shimizu M; Kawanami Y; Shimura K; Onishi C; Muramoto Y; Suzuki T; Sasaki J; Nagasaki Y; Minami R; Motozono C; Toyoda M; Takahashi H; Kishi H; Fujii K; Tatsuke T; Ikeda T; Maeda Y; Ueno T; Koyanagi Y; Iwagoe H; Matsushita S
    Cell Rep; 2021 Jul; 36(2):109385. PubMed ID: 34237284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emergency response for evaluating SARS-CoV-2 immune status, seroprevalence and convalescent plasma in Argentina.
    Ojeda DS; Gonzalez Lopez Ledesma MM; Pallarés HM; Costa Navarro GS; Sanchez L; Perazzi B; Villordo SM; Alvarez DE; ; Echavarria M; Oguntuyo KY; Stevens CS; Lee B; Carradori J; Caramelo JJ; Yanovsky MJ; Gamarnik AV
    PLoS Pathog; 2021 Jan; 17(1):e1009161. PubMed ID: 33444413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection.
    Wang Z; Muecksch F; Schaefer-Babajew D; Finkin S; Viant C; Gaebler C; Hoffmann HH; Barnes CO; Cipolla M; Ramos V; Oliveira TY; Cho A; Schmidt F; Da Silva J; Bednarski E; Aguado L; Yee J; Daga M; Turroja M; Millard KG; Jankovic M; Gazumyan A; Zhao Z; Rice CM; Bieniasz PD; Caskey M; Hatziioannou T; Nussenzweig MC
    Nature; 2021 Jul; 595(7867):426-431. PubMed ID: 34126625
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma.
    Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V
    J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neutralizing antibody responses to SARS-CoV-2 in symptomatic COVID-19 is persistent and critical for survival.
    Dispinseri S; Secchi M; Pirillo MF; Tolazzi M; Borghi M; Brigatti C; De Angelis ML; Baratella M; Bazzigaluppi E; Venturi G; Sironi F; Canitano A; Marzinotto I; Tresoldi C; Ciceri F; Piemonti L; Negri D; Cara A; Lampasona V; Scarlatti G
    Nat Commun; 2021 May; 12(1):2670. PubMed ID: 33976165
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decline of Humoral Responses against SARS-CoV-2 Spike in Convalescent Individuals.
    Beaudoin-Bussières G; Laumaea A; Anand SP; Prévost J; Gasser R; Goyette G; Medjahed H; Perreault J; Tremblay T; Lewin A; Gokool L; Morrisseau C; Bégin P; Tremblay C; Martel-Laferrière V; Kaufmann DE; Richard J; Bazin R; Finzi A
    mBio; 2020 Oct; 11(5):. PubMed ID: 33067385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern.
    Dupont L; Snell LB; Graham C; Seow J; Merrick B; Lechmere T; Maguire TJA; Hallett SR; Pickering S; Charalampous T; Alcolea-Medina A; Huettner I; Jimenez-Guardeño JM; Acors S; Almeida N; Cox D; Dickenson RE; Galao RP; Kouphou N; Lista MJ; Ortega-Prieto AM; Wilson H; Winstone H; Fairhead C; Su JZ; Nebbia G; Batra R; Neil S; Shankar-Hari M; Edgeworth JD; Malim MH; Doores KJ
    Nat Microbiol; 2021 Nov; 6(11):1433-1442. PubMed ID: 34654917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset.
    Xiang T; Liang B; Fang Y; Lu S; Li S; Wang H; Li H; Yang X; Shen S; Zhu B; Wang B; Wu J; Liu J; Lu M; Yang D; Dittmer U; Trilling M; Deng F; Zheng X
    Front Immunol; 2021; 12():708523. PubMed ID: 34220870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Heterogeneous antibodies against SARS-CoV-2 spike receptor binding domain and nucleocapsid with implications for COVID-19 immunity.
    McAndrews KM; Dowlatshahi DP; Dai J; Becker LM; Hensel J; Snowden LM; Leveille JM; Brunner MR; Holden KW; Hopkins NS; Harris AM; Kumpati J; Whitt MA; Lee JJ; Ostrosky-Zeichner LL; Papanna R; LeBleu VS; Allison JP; Kalluri R
    JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32796155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China.
    Feng X; Yin J; Zhang J; Hu Y; Ouyang Y; Qiao S; Zhao H; Zhang T; Li X; Zhang L; Zhang J; Jin R; Feng Y; Su B
    Front Immunol; 2021; 12():614436. PubMed ID: 33790892
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates.
    Boonyaratanakornkit J; Morishima C; Selke S; Zamora D; McGuffin S; Shapiro AE; Campbell VL; McClurkan CL; Jing L; Gross R; Liang J; Postnikova E; Mazur S; Lukin VV; Chaudhary A; Das MK; Fink SL; Bryan A; Greninger AL; Jerome KR; Holbrook MR; Gernsheimer TB; Wener MH; Wald A; Koelle DM
    J Clin Invest; 2021 Feb; 131(3):. PubMed ID: 33320842
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
    Robbiani DF; Gaebler C; Muecksch F; Lorenzi JCC; Wang Z; Cho A; Agudelo M; Barnes CO; Gazumyan A; Finkin S; Hägglöf T; Oliveira TY; Viant C; Hurley A; Hoffmann HH; Millard KG; Kost RG; Cipolla M; Gordon K; Bianchini F; Chen ST; Ramos V; Patel R; Dizon J; Shimeliovich I; Mendoza P; Hartweger H; Nogueira L; Pack M; Horowitz J; Schmidt F; Weisblum Y; Michailidis E; Ashbrook AW; Waltari E; Pak JE; Huey-Tubman KE; Koranda N; Hoffman PR; West AP; Rice CM; Hatziioannou T; Bjorkman PJ; Bieniasz PD; Caskey M; Nussenzweig MC
    Nature; 2020 Aug; 584(7821):437-442. PubMed ID: 32555388
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neutralizing antibody response elicited by SARS-CoV-2 receptor-binding domain.
    Huang PH; Tsai HH; Liao BH; Lin YL; Jan JT; Tao MH; Chou YC; Hu CJ; Chen HW
    Hum Vaccin Immunother; 2021 Mar; 17(3):654-655. PubMed ID: 32991231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2-specific circulating T follicular helper cells correlate with neutralizing antibodies and increase during early convalescence.
    Boppana S; Qin K; Files JK; Russell RM; Stoltz R; Bibollet-Ruche F; Bansal A; Erdmann N; Hahn BH; Goepfert PA
    PLoS Pathog; 2021 Jul; 17(7):e1009761. PubMed ID: 34270631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients.
    Muecksch F; Wise H; Batchelor B; Squires M; Semple E; Richardson C; McGuire J; Clearly S; Furrie E; Greig N; Hay G; Templeton K; Lorenzi JCC; Hatziioannou T; Jenks S; Bieniasz PD
    J Infect Dis; 2021 Feb; 223(3):389-398. PubMed ID: 33140086
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.
    Bonhomme ME; Bonhomme CJ; Strelow L; Chaudhari A; Howlett A; Breidenbach C; Hester J; Hammond C; Fuzy M; Harvey L; Swanner V; Ellis J; Greway RR; Pisciella VA; Green T; Kierstead L
    PLoS One; 2022; 17(2):e0262922. PubMed ID: 35130298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.
    Wirz OF; Röltgen K; Stevens BA; Pandey S; Sahoo MK; Tolentino L; Verghese M; Nguyen K; Hunter M; Snow TT; Singh AR; Blish CA; Cochran JR; Zehnder JL; Nadeau KC; Pinsky BA; Pham TD; Boyd SD
    Front Immunol; 2021; 12():739037. PubMed ID: 34594341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Studying the Humoral Response against SARS-CoV-2 in Cuban COVID-19 Recovered Patients.
    Orosa Vázquez I; Díaz M; Zúñiga Rosales Y; Amada K; Chang J; Relova Hernández E; Tundidor Y; Roblejo Balbuena H; Monzón G; Torres Rives B; Noa Romero E; Carrillo Valdés D; Valdivia Álvarez I; Delahanty Fernández A; Díaz C; Solozabal J; Gil M; Sánchez B; Rojas G; Marcheco B; Carmenate T
    J Immunol Res; 2024; 2024():7112940. PubMed ID: 39359695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD.
    Zhou Y; Liu Z; Li S; Xu W; Zhang Q; Silva IT; Li C; Wu Y; Jiang Q; Liu Z; Wang Q; Guo Y; Wu J; Gu C; Cai X; Qu D; Mayer CT; Wang X; Jiang S; Ying T; Yuan Z; Xie Y; Wen Y; Lu L; Wang Q
    Cell Rep; 2021 Feb; 34(5):108699. PubMed ID: 33485405
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants.
    Moriyama S; Adachi Y; Sato T; Tonouchi K; Sun L; Fukushi S; Yamada S; Kinoshita H; Nojima K; Kanno T; Tobiume M; Ishijima K; Kuroda Y; Park ES; Onodera T; Matsumura T; Takano T; Terahara K; Isogawa M; Nishiyama A; Kawana-Tachikawa A; Shinkai M; Tachikawa N; Nakamura S; Okai T; Okuma K; Matano T; Fujimoto T; Maeda K; Ohnishi M; Wakita T; Suzuki T; Takahashi Y
    Immunity; 2021 Aug; 54(8):1841-1852.e4. PubMed ID: 34246326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.